Welcome to our dedicated page for Teladoc Health SEC filings (Ticker: TDOC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Teladoc Health, Inc. (NYSE: TDOC) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its virtual care business, financial condition and governance. These SEC filings include current reports on Form 8-K, annual and quarterly reports, and other documents that describe material events, segment performance and capital structure decisions.
Recent Form 8-K filings for Teladoc Health have addressed topics such as quarterly financial results, preliminary earnings announcements, entry into a senior secured revolving credit facility, amendments to the company’s 2023 Employment Inducement Incentive Award Plan, and changes in executive leadership and Board composition. For example, the company has reported on its second and third quarter 2025 results, including revenue by type and geography, Integrated Care and BetterHelp segment performance, and adjusted EBITDA. It has also disclosed the establishment of a five-year revolving credit facility and amendments to its inducement equity plan to increase the number of shares reserved for issuance.
On this page, investors can review Teladoc Health’s SEC filings to understand how the company reports revenue from access fees and other sources, how it presents non-GAAP measures such as adjusted EBITDA, and how it describes its capital allocation priorities. Filings also provide information on leadership transitions, director decisions, and compensatory arrangements, including inducement awards of restricted stock units and performance stock units.
Stock Titan enhances access to these filings with AI-powered summaries that explain the key points of lengthy documents such as 10-K annual reports, 10-Q quarterly reports and 8-K current reports. Users can quickly see highlights related to Teladoc Health’s Integrated Care and BetterHelp segments, credit agreements, equity plans, and governance changes, while still being able to open the full SEC documents for complete details.
Teladoc Health’s chief legal officer and secretary reported routine stock activity related to vesting of prior equity awards. On December 1, 2025, 1,505 performance stock units and two blocks of restricted stock units (4,418 and 5,350 units) converted on a one-for-one basis into shares of Teladoc common stock. On December 2, 2025, 5,720 common shares were sold at $7.488 per share to satisfy tax withholding obligations tied to these vesting events. After these transactions, the officer directly owns 80,732 shares of common stock and continues to hold derivative awards, including performance and restricted stock units scheduled to vest over time.
Teladoc Health insider equity activity: A Teladoc Health officer, identified as President, International, reported routine equity compensation transactions involving company common stock. On December 1, 2025, the officer acquired 1,056 shares of Teladoc common stock through performance stock units converting on a one-for-one basis and an additional 3,101 shares and 4,556 shares through restricted stock units that also convert one-for-one into common stock. These awards stem from prior grants made in March 2023 and March 2024 with scheduled vesting over time.
On December 2, 2025, the officer sold 3,897 shares of Teladoc common stock at a price of $7.488 per share to cover tax withholding obligations related to the vesting of the performance and restricted stock units. Following these transactions, the officer continued to hold tens of thousands of Teladoc shares directly, reflecting ongoing equity ownership linked to prior stock unit grants.
Teladoc Health, Inc. officer reports stock unit vesting and tax-sale transaction. A Teladoc Health executive, serving as President, U.S. Group Health, reported the conversion of performance stock units and restricted stock units into common stock and a related sale of shares.
On 12/01/2025, 1,189 performance stock units and two blocks of restricted stock units totaling 8,346 units (3,488 and 4,858) converted into the same number of Teladoc common shares on a one-for-one basis. On 12/02/2025, 4,582 shares of common stock were sold at $7.488 per share to cover tax withholding obligations from these vestings.
After these transactions, the reporting person beneficially owned 60,054 shares of Teladoc common stock directly, along with remaining derivative holdings that include performance and restricted stock units scheduled to vest over time under prior grants.
TDOC insider Fernando Madeira Rodrigues filed a Form 144 to sell 4,209 common shares. The planned sale, with aggregate market value of 31,483.32, is to be executed through Fidelity Brokerage Services LLC on the NYSE around 12/03/2025. The issuer has 177,473,405 shares of common stock outstanding. These 4,209 shares were acquired on 12/01/2025 through restricted stock vesting from the issuer as compensation.
Over the prior three months, the same seller reported two additional sales of the issuer’s common stock: 4,149 shares on 09/03/2025 for gross proceeds of 31,490.91 and 2,324 shares on 12/02/2025 for gross proceeds of 17,402.81.
A shareholder filed a Rule 144 notice to sell 5,720 common shares of the issuer associated with symbol TDOC. The planned sale is to be executed through Fidelity Brokerage Services LLC on the NYSE on or about 12/02/2025, with an indicated aggregate market value of $42,833.07. The filing notes that there are 177,473,405 shares outstanding.
The 5,720 shares to be sold were acquired on 12/01/2025 through restricted stock vesting from the issuer as compensation. The notice also discloses that the same insider sold 5,867 common shares on 09/02/2025 for gross proceeds of $44,502.95. By signing, the seller represents that they are not aware of undisclosed material adverse information about the issuer’s current or prospective operations.
Teladoc Health insider plans sale of recently vested shares. A holder of Teladoc Health common stock filed a notice of proposed sale covering 3,897 shares to be sold through Fidelity Brokerage Services LLC on the NYSE, with an approximate sale date of 12/02/2025. These shares were acquired on 12/01/2025 through restricted stock vesting from the issuer as compensation. The filing notes that 177,473,405 shares of Teladoc Health common stock were outstanding. It also reports that the same seller disposed of 3,998 common shares on 09/02/2025 for gross proceeds of $30,326.03. The seller represents that they are not aware of undisclosed material adverse information about the company.
An affiliate of the company with symbol TDOC has filed a Rule 144 notice indicating an intent to sell 4,582 shares of common stock through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of 34,311.39. The filing notes that 177,473,405 shares of the issuer’s stock were outstanding at the time of the notice; this is a baseline figure, not the amount being sold.
The shares to be sold were acquired on 12/01/2025 via restricted stock vesting from the issuer as compensation, with payment recorded on the same date. The notice also reports that in the past three months, the same seller, identified as Kelly Bliss, sold 4,700 common shares on 09/02/2025 for gross proceeds of 35,650.91.
A shareholder of TDOC has filed a Form 144 notice to sell 2,324 shares of common stock through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of $17,402.81. The shares are part of a much larger base of 177,473,405 common shares outstanding.
The stock to be sold was acquired on 12/01/2025 through restricted stock vesting from the issuer as compensation. The same seller previously sold 2,383 and 4,149 common shares on 09/02/2025 and 09/03/2025, generating gross proceeds of $18,075.77 and $31,490.91. By signing the notice, the seller represents they do not know of any undisclosed material adverse information about the issuer’s current or prospective operations.
Teladoc Health, Inc. director reports open-market stock purchase
A Teladoc Health, Inc. director filed a Form 4 reporting the purchase of 10,000 shares of the company’s common stock. The transaction took place on 11/14/2025 at a price of $6.94 per share, resulting in beneficial ownership of 10,000 shares following the trade, held directly.
The filing notes that this transaction was carried out under a Rule 10b5-1 trading plan that the reporting person adopted on August 15, 2025. Rule 10b5-1 plans are pre-arranged trading programs intended to allow insiders to buy or sell shares according to preset instructions.
Teladoc Health (TDOC): Schedule 13G/A update on ownership
Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen reported beneficial ownership of 5,795,178 Teladoc common shares, representing 3.3% of the class as of September 30, 2025. The filers report shared voting and dispositive power over 5,795,178 shares and no sole voting or dispositive power.
The certification states the securities were not acquired and are not held for the purpose of changing or influencing control of Teladoc. This amendment formalizes current holdings and roles among the reporting persons, including Mr. Cohen’s indirect control of the reporting entities.